Abbott Laboratories Director Receives Quarterly Stock Equivalent Units

Executive Summary

On October 2, 2026, Abbott Laboratories ($ABT) filed a Form 4 with the SEC disclosing an acquisition by Director Michael F. Roman. On September 30, 2026, Roman acquired 381 Stock Equivalent Units valued at $98.83 per unit, representing a total transaction value of $37,654.23.

Transaction Details

• Security: Stock Equivalent Units (convertible into Common Shares on a 1-for-1 basis)
• Transaction Code: 'A' (Grant, award, or other acquisition under Rule 16b-3)
• Units Transacted: 381
• Price per Unit: $98.83
• Total Value: $37,654.23
• Beneficial Ownership Following Transaction: 7,166 Stock Equivalent Units (held directly)

Context and Footnote Analysis

Per the filing footnotes, the transaction reflects regular director fees credited to a stock equivalent unit account. These units are settled in cash generally upon reaching age 65 or retiring from the board, tracking the economic performance of Abbott common stock. The post-transaction balance also reflects units accumulated via dividend reinvestment.

Trading Significance

The trading significance of this event is Low. This is an automated, routine quarterly compensation grant tied to board service fees rather than an open-market, discretionary purchase or sale.